Richmond Pharmacology (RPL) will be attending this month's 22nd Annual DIA EuroMeeting, taking place 8-10 March 2010 in Monaco.

Posted:
1
March 2010

Richmond Pharmacology (RPL) will be attending this month�s 22nd Annual DIA EuroMeeting, taking place 8-10 March 2010 in Monaco.The DIA Annual EuroMeeting features more than 110 hot-topic sessions across 13 themes and attracts more than 3,000 professionals from the biopharmaceutical industry, contract service organisations, regulatory agencies, health ministries and academia, as well as patients and students worldwide.Themes are based on an integrated multidisciplinary approach that will generate interest from as many disciplines as possible. This year�s themes include:

  • Innovation
  • Staying in Business: How to Make Sure You Comply with All Rules and Regulations
  • Paediatric Medicines on Their Way to Patients
  • Decision Making: The Key to Efficient and Effective Drug Development, approval, and access
  • Paving the Way for Advanced Therapies: Fostering New Generations of Biotechnology-Derived Medicines
  • Challenges for Switching from Prescription to Non-Prescription Status through the Centralised Procedure
  • Personalised Medicines: What Is It, Where Do We Stand, and Where Are We Going?
  • Taking the European Regulatory Infrastructure Forward
  • Risk Management
  • The Informed Patient
  • eHealth
  • Pharmaceutical Sciences in 2020
  • Handling Clinical Trials, eSubmissions and Quality Requests

Click here to download advanced programme.RPL will be exhibiting at this year�s DIA EuroMeeting to inform key decision makers in the industry of our expertise and experience in the field of Early Phase Research. The EuroMeeting is a key event in the calendar and this forum provides an ideal opportunity to meet with existing clients, network and connect with new prospective sponsors. Planning to attend? We look forward to seeing you in Monaco next month!

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more